|
NEXMED FILES NDS
IN CANADA
|
|
East Windsor,
NJ, October 22 , 2007 --
NexMed, Inc. (Nasdaq: NEXM),
a developer of innovative transdermal
products based on its proprietary
NexACT drug delivery technology,
today announced that it filed
the New Drug Submission (NDS)
for its topical alprostadil
treatment for erectile dysfunction
with Health Canada on October
19, 2007. Health Canada customarily
accepts or refuses an NDS and
designates review status within
forty five (45) days of filing.
Once accepted, Health Canada's
target is to complete review
within three hundred (300) days
for ninety percent (90%) of
submissions.
|
|
|
|
| About NexMed,
Inc. |
|
NexMed, Inc. is an emerging
drug developer that is leveraging
its proprietary drug technology
to develop a significant pipeline
of innovative pharmaceutical products
to address significant unmet medical
needs. The Company is also working
with various pharmaceutical companies
to explore the incorporation of
NexACT into their existing drugs
as a means of developing new patient-friendly
transdermal products and extending
patent lifespans and brand equity.
Statements under the Private Securities
Litigation Reform Act: with the
exception of the historical information
contained in this release, the
matters described herein contain
forward-looking statements that
involve risk and uncertainties
that may individually or mutually
impact the matters herein described,
including but not limited to whether
Health Canada will accept the
Company's NDS. |
|
|
|
|
